Want to see IL:BOLT full AI Analyst Report?
Top Page
Biolight
(TASE:BOLT)
Select Model
Select Model
Rating:41Neutral
Price Target:
280.00
▼(-15.05% Downside)
Action:Reiterated
Date:08/21/26
The score is driven down primarily by weak financial performance (minimal/zero revenue, sustained losses, and persistent cash burn), reinforced by poor technical momentum with the price below key moving averages and negative MACD. Valuation metrics provide limited support because losses make the P/E uninformative and no dividend yield is available.
Positive Factors
Very Low Leverage
Very low leverage limits refinancing and solvency pressure, preserving more financial flexibility than a highly indebted structure. This can help the company withstand operating weakness and retain options for funding development, even though losses continue to reduce equity.
Negative Factors
Minimal and Volatile Revenue
Extremely small and volatile revenue indicates that the business has not yet demonstrated repeatable commercial scale. Zero revenue in 2025 leaves little operating coverage for the cost base and makes future funding and profitability highly dependent on successful commercialization.
Read all positive and negative factors
Positive Factors
Negative Factors
Very Low Leverage
Very low leverage limits refinancing and solvency pressure, preserving more financial flexibility than a highly indebted structure. This can help the company withstand operating weakness and retain options for funding development, even though losses continue to reduce equity.
Read all positive factors
Biolight (BOLT) vs. iShares MSCI Israel ETF (EIS)
Market Cap
₪26.58M
Dividend YieldN/A
Average Volume (3M)9.85K
Price to Earnings (P/E)―
Beta (1Y)0.57
Revenue Growth-100.00%
EPS Growth-29.02%
CountryIL
Employees4
SectorGeneral
Sector StrengthN/A
IndustryMedical - Specialties
Share Statistics
EPS (TTM)-1.34
Shares Outstanding9,079,270
10 Day Avg. Volume2,744
30 Day Avg. Volume9,848
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)0.61
Price to Sales (P/S)0.00
P/FCF Ratio-1.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Biolight Business Overview & Revenue Model
Company Description
BioLight Life Sciences Ltd. is an ophthalmic firm dedicated to discovering, developing, and bringing to market innovative products and pipeline candidates designed to tackle various eye-related ailments. Its portfolio and development pipeline incl...
Biolight Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Mar 2026 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 219.00K | 118.00K | 63.00K | 3.00K |
| Gross Profit | -270.00K | -544.00K | 219.00K | 118.00K | 63.00K | 3.00K |
| EBITDA | -14.65M | -14.66M | -7.75M | -10.60M | -8.03M | -1.31M |
| Net Income | -11.74M | -11.73M | -7.14M | -26.02M | -7.85M | 382.00K |
Balance Sheet | ||||||
| Total Assets | 35.06M | 42.41M | 34.12M | 33.45M | 57.01M | 64.17M |
| Cash, Cash Equivalents and Short-Term Investments | 16.19M | 23.65M | 13.47M | 8.64M | 17.63M | 33.71M |
| Total Debt | 1.06M | 772.00K | 599.00K | 91.00K | 527.00K | 443.00K |
| Total Liabilities | 3.86M | 2.24M | 3.38M | 3.15M | 3.32M | 2.75M |
| Stockholders Equity | 28.09M | 34.40M | 26.88M | 29.78M | 53.17M | 60.70M |
Cash Flow | ||||||
| Free Cash Flow | -11.92M | -10.86M | -11.02M | -10.99M | -9.64M | -10.65M |
| Operating Cash Flow | -11.92M | -10.85M | -10.99M | -9.58M | -9.54M | -10.03M |
| Investing Cash Flow | -11.96M | -16.17M | 7.55M | -1.95M | -10.55M | 13.48M |
| Financing Cash Flow | 21.36M | 21.37M | 7.98M | 3.25M | -485.00K | 915.00K |
Biolight Technical Analysis
Negative
329.60
Price Trends
338.03
Negative
326.07
Negative
331.45
Negative
Market Momentum
-9.76
Negative
42.19
Neutral
92.46
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:BOLT, the sentiment is Negative. The current price of 329.6 is above the 20-day moving average (MA) of 294.49, below the 50-day MA of 338.03, and below the 200-day MA of 331.45, indicating a bearish trend. The MACD of -9.76 indicates Negative momentum. The RSI at 42.19 is Neutral, neither overbought nor oversold. The STOCH value of 92.46 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IL:BOLT.
Biolight Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
46 Neutral | ₪32.42M | >-0.01 | ― | 0.96% | ― | -125.74% | |
45 Neutral | ₪37.82M | -1.38 | ― | ― | -93.07% | 62.25% | |
41 Neutral | ₪26.58M | -2.18 | ― | ― | -100.00% | -29.02% | |
40 Underperform | ₪21.21M | -0.33 | ― | ― | ― | ― |
* General Sector Average
IL:BOLT
Biolight
292.70
-113.30
-27.91%
IL:BONS
Bonus Biogroup
19.90
-2.20
-9.95%
IL:CBI
Clal Biotech
24.30
-13.10
-35.03%
IL:BLRX
Bioline Rx
1.30
-0.80
-38.10%
IL:CANF
Can Fite Bio
349.90
348.90
34890.00%
IL:PPBT
Purple Biotech
1.00
0.00
0.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.